- Email Preferences
- Logout

+44 (0)20 8762 8008
Change Language
[Close]
- English
  
  Japanese
  
  English
Home
Overview
- Pandemic
- Bird Flu
Subscribers
Locations
Newsroom
- News
- Editorials
- FAQs

Quick Links

COVID-19

Public Access

Interactive COVID-19 Data by Location

COVID-19 Case Count Trackers

Education and Communication

COVID-19 FAQs and External Resources

COVID-19 Videos

Member Access

Travel Restrictions, Flight Operations and Screening

COVID-19 Digital Passports

Scientific Update

COVID-19 FAQs

COVID-19 Vaccine

COVID-19 Vaccine FAQs

COVID-19 Variants

COVID-19 Testing

COVID-19 Treatment

Use of Face Masks by the General Public

COVID-19 Travel Advice

COVID-19 Disease and Prevention Article

Sign up for Emails and Alerts

Premium Services Member Access

COVID-19 Manager Advice

COVID-19 Case Definitions used by different authorities

Pandemic Local Impact Tool

COVID-19 Communication Material

COVID-19 Modelling

COVID-19 Useful Links

…
65
66
67
68
69
…

COVID-19 restrictions update - outdoor meeting of up to six people allowed
United Kingdom // 29 March, 2021
As of 29 March...
COVID-19
ECDC report on challenges of COVID-19 vaccine rollout in the EU and UK
29 March, 2021
Challenges include limited suppy of vaccines and equipment to administer vaccines...
COVID-19
Rise in COVID-19 infections in people who had first vaccine dose, likely due to relaxing preventive measures
United Kingdom // Israel // 28 March, 2021
People are letting their guard down before the vaccine has taken effect....
COVID-19
Further Evidence Supports Remdesivir as Treatment for COVID-19
27 March, 2021
Treatment reduced time to recovery by several days…
COVID-19
Study: SARS-CoV-2 can infect the mouth and salivary glands
26 March, 2021
Saliva could be a potential route of transmission...
COVID-19
LY-CoV555 antibody monotherapy halted
United States // 26 March, 2021
Variant viruses show resistance to LY-CoV555 treatment, distribution halted...
COVID-19
US Data shows AstraZeneca slightly less effective but no major safety concerns
25 March, 2021
Latest data shows no major safety concerns
COVID-19
Vaccine Update - Vaccinations for homebound persons available
Anguilla // 25 March, 2021
The vaccination team will visit homebound persons in each health district...
COVID-19
PAHO publishes review of variant viruses in the Americas region
24 March, 2021
All three main variants of concern have been detected in the Americas region, with many countries having more than one...
COVID-19
Study: vaccinated healthcare workers at low risk for COVID
United States // 24 March, 2021
Vaccinated healthcare workers showed low rates of infection during...
COVID-19
Oral treatments for COVID in trials
24 March, 2021
Early study showed the pill may have shortened the period during which COVID patients....
COVID-19
Vaccine Update - Vaccination open to everyone over 16 years
Guam // 24 March, 2021
Vaccination is now available to all residents over 16 years of age...
COVID-19
UK variant of SARS-CoV-2 found in animals
United States // United Kingdom // Italy // 24 March, 2021
Animals diagnosed with the B.1.1.7 variant of SARS-CoV-2 have been reported in...
COVID-19
Vaccine update – Estonia vaccinated 14.1% of it’s population
Estonia // 23 March, 2021
The vaccination campaign is proceeding well, with approximately 1 in 7 adults in Estonia vaccinated…
COVID-19
CureVac vaccine candidate: Pre-clinical data in mice show robust antibody response against B.1.351 strain
23 March, 2021
Pre-clinical data in mice show robust antibody response against B.1.351 strain...
COVID-19
Inhaled COVID-19 vaccine approved for trials in China
China // 23 March, 2021
Cansino Biotech to start clinical trials of inhaled vaccine...
COVID-19
Infection with human rhinovirus blocks SARS-CoV-2 replication, study
23 March, 2021
"...likely to have a population-wide effect as an increasing prevalence of rhinovirus will reduce the number of new COVID-19 cases."
COVID-19
Children produce different antibodies for SARS-CoV-2 compared with adults: studies
23 March, 2021
Study finds young kids have strongest immune response to COVID-19...
COVID-19
Oral, nasal COVID-19 vaccine candidates
India // 23 March, 2021
Oral and nasal vaccine candidates in India to undergo clinical trials
COVID-19
Covishield second dose at 4 - 8 weeks
India // 23 March, 2021
Interval between first and second doses of Covishield increased
COVID-19

…
65
66
67
68
69
…

Additional data provided by

© 2024 International SOS